Business, Mid-Market & Industrial

How to Underwrite a Medical Device Company

Underwrite a medical device company by confirming the regulatory status of every revenue-generating product, then testing reimbursement durability and quality system health before modeling cash flow. The key metrics are revenue from cleared or approved products, gross margin on disposables versus capital equipment, and complaint, MDR and recall trends. An open FDA warning letter undermines leverage.

What makes medical devices underwriting different

Medical device businesses sit behind a regulatory moat that is valuable but fragile. Revenue depends on FDA clearance or approval, CE marking for international sales, and in many cases a reimbursement code that lets hospitals or physicians get paid for using the product. Value comes from recurring disposables tied to an installed base, sticky surgeon or clinician preference, and intellectual property that blocks competitors. Risk comes from quality system failures, recalls, product liability, changes in reimbursement, and dependence on a small number of distributors or key opinion leaders. Contract manufacturers in the space carry similar regulatory burdens but depend on OEM customers rather than end users.

Lenders look for products already on market with demonstrated reimbursement, consistent gross margins and a quality system that has passed recent inspections. They avoid lending against pipeline products and typically haircut revenue from capital equipment because hospital purchasing is lumpy. Equity investors underwrite the pipeline and indications expansion as well as current sales, valuing new clearances, label expansions and international registrations. Growth equity will accept clinical and regulatory risk that a senior lender will not, so the capital structure often mixes modest senior debt with significant equity or venture debt in earlier-stage companies.

Key metrics

Revenue mix: disposables vs capital equipment

Recurring disposables used per procedure are far more predictable than one-time capital sales that depend on hospital budgets.

Lenders typically assign more value and leverage capacity to recurring disposable revenue than to capital equipment sales.

Gross margin by product line

Device margins are often high, and erosion signals pricing pressure from group purchasing organizations or rising manufacturing costs.

Complaint, MDR and recall trends

Rising complaints or medical device reports can precede recalls, warning letters and product liability claims.

Surgeon or account concentration

In procedure-driven devices, a few high-volume physicians or hospital systems can drive a disproportionate share of usage.

Days sales outstanding

Hospital and distributor payment cycles can be slow, and consignment inventory at hospitals ties up working capital.

R&D and regulatory spend as a percent of revenue

Maintaining clearances and launching next-generation products requires ongoing investment that should not be cut to inflate EBITDA.

How to underwrite it, step by step

Inventory every product, its FDA classification, 510(k), De Novo or PMA status, CE mark status and the revenue each generates.
Review FDA inspection history, Form 483 observations, warning letters and the status of corrective and preventive actions.
Analyze complaint files, MDR filings and recall history for trends by product line.
Confirm reimbursement codes, coverage policies and payment rates for procedures using the device.
Diligence patents, freedom to operate, and licenses for core technology.
Analyze customer, distributor and surgeon concentration, including GPO contracts and pricing tiers.
Normalize EBITDA for R&D capitalization, consignment inventory and one-time regulatory costs.
Stress the model for a recall, a reimbursement cut and the loss of a key distributor or surgeon group.

Due diligence checklist

510(k) clearances, PMA approvals and De Novo grants with product mapping
FDA establishment registration and device listings
FDA inspection reports, Form 483s, warning letters and responses
Quality management system documentation and ISO 13485 certificates
Complaint logs, MDR filings and recall records
Reimbursement analysis including CPT and HCPCS codes and coverage policies
Patent portfolio, freedom to operate opinions and license agreements
Distributor and GPO agreements with pricing terms
Revenue by product, customer and physician
Consignment and field inventory reports
Product liability insurance and claims history
Clinical study reports supporting current indications

Key risks and mitigants

Quality system failure or FDA enforcement

Engage a regulatory consultant to audit the quality system, require remediation milestones, and include FDA events in MAC and reporting covenants.

Product recall

Review complaint trends and CAPA effectiveness, confirm recall insurance, and size liquidity to absorb a recall-related revenue gap.

Reimbursement cut or loss of coverage

Model revenue at lower payment rates and diligence the coding and coverage history for the procedure.

IP challenge or competitor design-around

Obtain freedom to operate analysis and assess remaining patent life on core products.

Distributor or key surgeon dependence

Review distributor contract terms and transition rights, and analyze procedure volume by physician.

Product liability litigation

Review claims history, confirm insurance limits and consider specific indemnities or escrows for known issues.

Typical financing and deal structure

Profitable, mid-market device companies with established products are financed with senior term loans and revolvers from banks or private credit lenders, often at conservative leverage given regulatory and liability risk. Revenue-based financing and royalty financing are used where a single product drives cash flow. Earlier-stage companies with cleared products but limited profitability commonly use venture debt alongside equity, with warrants and minimum liquidity covenants. Acquisitions often include earnouts tied to regulatory milestones such as a new clearance or reimbursement decision. Purchase agreements typically include specific indemnities for known quality or regulatory issues, since representation and warranty insurance generally excludes them. Covenants usually include leverage and coverage tests plus regulatory reporting requirements.

Red flags

An open FDA warning letter or unresolved Form 483 observations on core products
Revenue from products without the required clearance or used off-label as a primary indication
Rising complaint and MDR trends without corresponding CAPA activity
Reliance on a single reimbursement code under review by payers
A key patent expiring within the loan term with no follow-on protection

Frequently asked questions

What do lenders look for in a medical device company?

Lenders want products already cleared or approved and generating revenue, a clean or well-remediated FDA inspection history, stable gross margins and recurring revenue from disposables. They review reimbursement status, customer concentration and product liability exposure. Pipeline products and pending clearances generally receive little or no credit in debt sizing, though they matter greatly to equity investors.

How does FDA status affect valuation?

Clearance or approval establishes the right to sell in the United States and creates a barrier to competitors. Products with PMA approval usually have stronger protection than 510(k) products because the pathway is costlier for competitors. Open warning letters, consent decrees or recall activity can sharply reduce valuation and may block financing until resolved.

Why is reimbursement important in medical device deals?

If hospitals or physicians are not paid adequately for procedures using a device, adoption stalls. Underwriters confirm the coding, coverage policies and payment rates that support the product, and test how revenue would change if rates fell. A device that is clinically strong but poorly reimbursed often grows more slowly than projections assume.

How do you underwrite a medical device contract manufacturer?

A contract manufacturer is underwritten on OEM customer concentration, contract terms, quality certifications such as ISO 13485, and its inspection history. Because switching manufacturers requires regulatory validation, relationships are sticky, but losing one large OEM program can still remove significant revenue. Capacity utilization, cleanroom capability and program pipeline also drive value.

Underwrite a medical devices deal in minutes

Drop a deck or data room. Underridge returns a verdict, investment memo, term sheet and a live model, with every headline figure traced to a page, a formula or a labeled assumption. Ten underwrites free.

Try Underridge free

Educational content, not investment, credit, legal or tax advice. Benchmarks are common practitioner rules of thumb and vary by lender, market and cycle.